Physician profile
Rita Melkonian
NPI 1497865836
$5,746.81
in general payments reported to CMS, 2019-2025
20 companies · $597 in 2025
The $597 reported for 2025 was more than what 79% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $827 · 2021: $1,032 · 2022: $841 · 2023: $844 · 2024: $835 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.42 |
| Education | $219.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,512.00 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $882.44 | 2021-2025 | |
| Pfizer INC. | $875.67 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $585.21 | 2023-2025 | Gemtesa |
| Therapeuticsmd, INC. | $558.87 | 2019-2022 | |
| Abbvie INC. | $249.63 | 2019-2022 | |
| Avion Pharmaceuticals | $199.26 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $155.18 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $137.87 | 2022 | |
| Ascend Therapeutics US, LLC | $106.32 | 2021-2023 | |
| Urovant Sciences INC | $103.38 | 2021-2022 | |
| Scynexis, INC. | $99.30 | 2022 | |
| Amag Pharmaceuticals, INC. | $80.00 | 2019 | |
| Hologic Sales and Service, LLC | $58.35 | 2019-2020 | |
| Allergan, INC. | $31.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.19 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $27.39 | 2024 | |
| Millicent US INC | $20.32 | 2025 | Femlyv |
| Myovant Sciences INC. | $18.76 | 2021 | |
| Lupin INC. | $17.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Melkonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.